{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:38:28Z","timestamp":1776577108723,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["K23MD019644"],"award-info":[{"award-number":["K23MD019644"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00520-025-10182-9","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T03:34:56Z","timestamp":1764128096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support"],"prefix":"10.1007","volume":"33","author":[{"given":"Ryan","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed M.","family":"Shanshal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Dimou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushal","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian R.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P.","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-189X","authenticated-orcid":false,"given":"Aminah","family":"Jatoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Cathcart-Rake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"19","key":"10182_CR1","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ, CROWN Trial Investigators (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(19):2018\u20132029. https:\/\/doi.org\/10.1056\/NEJMoa2027187","journal-title":"N Engl J Med"},{"key":"10182_CR2","doi-asserted-by":"publisher","unstructured":"Solomon BJ, Liu G, Felip E, K Mok TS, Soo RA, Mazieres J, Shaw AT, Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM (2024) Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer. Future Oncol 20(40):3377\u20133387.  https:\/\/doi.org\/10.1080\/14796694.2024.2406117","DOI":"10.1080\/14796694.2024.2406117"},{"issue":"4","key":"10182_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","volume":"11","author":"BJ Solomon","year":"2023","unstructured":"Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, L\u00f3pez FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E (2023) Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 11(4):354\u2013366. https:\/\/doi.org\/10.1016\/S2213-2600(22)00437-4","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10182_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1159\/000540445","volume":"17","author":"Y Fujiwara","year":"2024","unstructured":"Fujiwara Y, Masago K, Matsuzawa R, Yamaguchi T, Watanabe N, Shimizu J, Sasaki E, Horio Y (2024) Long-term response of lorlatinib to leptomeningeal metastasis in patients with anaplastic lymphoma kinase fusion positive non-small lung cancer: a case report. Case Rep Oncol 17(1):942\u2013949. https:\/\/doi.org\/10.1159\/000540445","journal-title":"Case Rep Oncol"},{"issue":"23","key":"10182_CR5","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1111\/1759-7714.15395","volume":"15","author":"Y Sato","year":"2024","unstructured":"Sato Y, Sato Y, Irie K, Nanjo S, Hara S, Fujiwara S, Tomii K (2024) Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: implications of CNS penetration rate of brigatinib. Thorac Cancer 15(23):1772\u20131775. https:\/\/doi.org\/10.1111\/1759-7714.15395","journal-title":"Thorac Cancer"},{"issue":"5","key":"10182_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","volume":"32","author":"E Felip","year":"2021","unstructured":"Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F, Abbattista A, Thurm H, Peltz G, Wiltshire R, Besse B (2021) Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 32(5):620\u2013630. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.012","journal-title":"Ann Oncol"},{"issue":"1","key":"10182_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","volume":"15","author":"TM Bauer","year":"2020","unstructured":"Bauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, Pithavala YK, Abbattista A, Peltz G, Felip E (2020) Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. Target Oncol 15(1):55\u201365. https:\/\/doi.org\/10.1007\/s11523-020-00702-4","journal-title":"Target Oncol"},{"issue":"14","key":"10182_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142611","volume":"16","author":"JN Priantti","year":"2024","unstructured":"Priantti JN, Vilbert M, de Moraes FCA, Madeira T, de Lima Santiago EM, Leighl NB, Cavalcante L, Karim NFA (2024) Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: a systematic review and meta-analysis. Cancers (Basel) 16(14):2611. https:\/\/doi.org\/10.3390\/cancers16142611","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10182_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jtho.2022.09.219","volume":"18","author":"I Dagogo-Jack","year":"2023","unstructured":"Dagogo-Jack I, Abbattista A, Murphy JF, Krulewicz S, Do A, Peterson J, Lin JJ, Gainor JF, Messina R, Krueger EA, Thurm H, Yeap BY (2023) Factors associated with developing neurocognitive adverse events in patients receiving lorlatinib after progression on other targeted therapies. J Thorac Oncol 18(1):67\u201378. https:\/\/doi.org\/10.1016\/j.jtho.2022.09.219","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10182_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.cllc.2023.12.003","volume":"25","author":"J Schoenmaekers","year":"2024","unstructured":"Schoenmaekers J, Dijkstra J, van der Wekken A, Paats M, Broen M, Brandts L, Dingemans AM, Hendriks L (2024) In-depth analysis of lorlatinib-related neurocognitive adverse events in patients with non-small-cell lung cancer. Clin Lung Cancer 25(2):168-174.e1. https:\/\/doi.org\/10.1016\/j.cllc.2023.12.003","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"10182_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100546","volume":"4","author":"R Thummalapalli","year":"2023","unstructured":"Thummalapalli R, Choudhury NJ, Ehrich F, Beardslee T, Brazel D, Zhang SS, Merchant S, Chen MF, Heller G, Ramalingam SS, Ou SI, Mileham KF, Riely GJ (2023) Lorlatinib tolerability and association with clinical outcomes in patients with advanced ALK- or ROS1-rearranged NSCLC: a brief report. JTO Clin Res Rep 4(8):100546. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100546","journal-title":"JTO Clin Res Rep"},{"key":"10182_CR12","unstructured":"https:\/\/lorbrena.pfizerpro.com\/therapy-management-dosing?cmp=151785263973&utm_source=MICROSOFT&utm_medium=paidsearch&pid=Lorbrena_BINGMSN_PON_LOR_BR_HCP_CON_PHR_BRN_BRA_GM_ENG_E0002IEW_SEA_PP-LOR-USA-0434_9\/11\/2025&utm_campaign=20420025985&utm_content=898447059528&utm_term=lorlatinib%20adverse%20reaction&gclid=8ca7a5f7e33611332ab1cde17322dbe7&gclsrc=3p.ds&gad_source=7. Last Accessed 8 Jul 2025"},{"issue":"11","key":"10182_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/pon.70025","volume":"33","author":"CH Kroenke","year":"2024","unstructured":"Kroenke CH, Kwan ML, Gomez SL, Shim V, Ergas IJ, Roh J, Kushi LH (2024) Social support and treatment delays in breast cancer patients within an integrated health care system. Psychooncology 33(11):e70025. https:\/\/doi.org\/10.1002\/pon.70025","journal-title":"Psychooncology"},{"key":"10182_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15712","author":"M Reitmajer","year":"2025","unstructured":"Reitmajer M, Sch\u00e4ffeler N, Bach A, Nanz L, Amaral T, Leiter U, Flatz L, Forschner A (2025) Psychosocial distress and persistent adverse events in long-term survivors of stage IV melanoma - a cross-sectional questionnaire study. JDDG J Dtsch Dermatol Ges. https:\/\/doi.org\/10.1111\/ddg.15712","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"10182_CR15","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.1812","volume":"18","author":"R Daruvala","year":"2024","unstructured":"Daruvala R, Misra R, Nair B, Siddiqui H, Banerji U, Crabtree VM, Arora RS (2024) Delivering psychological and social support to children with cancer in India and their families: a position statement from the social and psychological taskforce of the Indian childhood cancer initiative. Ecancermedicalscience 18:1812. https:\/\/doi.org\/10.3332\/ecancer.2024.1812","journal-title":"Ecancermedicalscience"},{"key":"10182_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhlto.2024.100079","volume":"4","author":"L Azap","year":"2024","unstructured":"Azap L, Diaz A, Gouchoe DA, Mokadam NA, Smith S, Henn MC, Whitson BA, Habib A, Lampert BC, Pawlik TM, Ganapathi AM (2024) Trends in survival after heart transplantation based on Social Vulnerability Index in the United States. JHLT Open 4:100079. https:\/\/doi.org\/10.1016\/j.jhlto.2024.100079","journal-title":"JHLT Open"},{"issue":"2","key":"10182_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1358\/dot.2019.55.2.2927983","volume":"55","author":"T Akamine","year":"2019","unstructured":"Akamine T, Toyokawa G, Tagawa T, Yamazaki K, Seto T, Takeo S, Mori M (2019) Lorlatinib for the treatment of patients with non-small cell lung cancer. Drugs Today (Barc) 55(2):107\u2013116. https:\/\/doi.org\/10.1358\/dot.2019.55.2.2927983","journal-title":"Drugs Today (Barc)"},{"issue":"6","key":"10182_CR18","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1007\/s12325-020-01365-3","volume":"37","author":"M Reed","year":"2020","unstructured":"Reed M, Rosales AS, Chioda MD, Parker L, Devgan G, Kettle J (2020) Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. Adv Ther 37(6):3019\u20133030. https:\/\/doi.org\/10.1007\/s12325-020-01365-3","journal-title":"Adv Ther"},{"key":"10182_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jad.2021.07.017","volume":"294","author":"MC Vance","year":"2021","unstructured":"Vance MC, Chang MM, Sussman JB, Zivin K, Pfeiffer PN (2021) Predicting clinically significant response to primary care treatment for depression from electronic health records of veterans. J Affect Disord 294:337\u2013345. https:\/\/doi.org\/10.1016\/j.jad.2021.07.017","journal-title":"J Affect Disord"},{"issue":"15","key":"10182_CR20","doi-asserted-by":"publisher","first-page":"E155","DOI":"10.5888\/pcd15.180371","volume":"13","author":"PY Chan","year":"2018","unstructured":"Chan PY, Zhao Y, Lim S, Perlman SE, McVeigh KH (2018) Using calibration to reduce measurement error in prevalence estimates based on electronic health records. Prev Chronic Dis 13(15):E155. https:\/\/doi.org\/10.5888\/pcd15.180371","journal-title":"Prev Chronic Dis"},{"key":"10182_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/08989621.2024.2449041","author":"G Tang","year":"2025","unstructured":"Tang G (2025) Using mixed methods research to study research integrity: current status, issues, and guidelines. Account Res. https:\/\/doi.org\/10.1080\/08989621.2024.2449041","journal-title":"Account Res"},{"issue":"Suppl 2","key":"10182_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11577-017-0454-1","volume":"69","author":"J Schoonenboom","year":"2017","unstructured":"Schoonenboom J, Johnson RB (2017) How to construct a mixed methods research design? Kolner Z Soz Sozpsychol 69(Suppl 2):107\u2013131. https:\/\/doi.org\/10.1007\/s11577-017-0454-1","journal-title":"Kolner Z Soz Sozpsychol"},{"issue":"6 Pt 2","key":"10182_CR23","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1111\/1475-6773.12117","volume":"48","author":"MD Fetters","year":"2013","unstructured":"Fetters MD, Curry LA, Creswell JW (2013) Achieving integration in mixed methods designs-principles and practices. Health Serv Res 48(6 Pt 2):2134\u20132156. https:\/\/doi.org\/10.1111\/1475-6773.12117","journal-title":"Health Serv Res"},{"issue":"1","key":"10182_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-019-0917-z","volume":"19","author":"C Pettigrew","year":"2019","unstructured":"Pettigrew C, Soldan A (2019) Defining cognitive reserve and implications for cognitive aging. Curr Neurol Neurosci Rep 19(1):1. https:\/\/doi.org\/10.1007\/s11910-019-0917-z","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"11","key":"10182_CR25","doi-asserted-by":"publisher","DOI":"10.2196\/64083","volume":"2","author":"H Huebner","year":"2025","unstructured":"Huebner H, Wurmthaler LA, Goossens C, Ernst M, Mocker A, Kr\u00fcckel A, Kallert M, Geck J, Limpert M, Seitz K, Ruebner M, Kreis P, Heindl F, H\u00f6rner M, Volz B, Roth E, Hack CC, Beckmann MW, Uhrig S, Fasching PA (2025) A digital home-based health care center for remote monitoring of side effects during breast cancer therapy: prospective, single-arm, monocentric feasibility study. JMIR Cancer 2(11):e64083. https:\/\/doi.org\/10.2196\/64083","journal-title":"JMIR Cancer"},{"issue":"6","key":"10182_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae102","volume":"8","author":"SD Lambert","year":"2024","unstructured":"Lambert SD, Soldera S, Kazdan J, Frati F, Slominska A, Boutin M, Samouelian V, Letendre C, Bilodeau K, Howell D, Breton KL, Gratton MO (2024) Patient-reported outcome measure (PROM) programs for monitoring symptoms among patients treated with immunotherapy: a scoping review. JNCI Cancer Spectr 8(6):pkae102. https:\/\/doi.org\/10.1093\/jncics\/pkae102","journal-title":"JNCI Cancer Spectr"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10182-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10182-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10182-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:32:26Z","timestamp":1765949546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10182-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10182"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10182-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Other than what is listed in the manuscript, no other human ethics, consent, and participant declarations are necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The consent to publish declaration is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AD reports honoraria to institution from Multimedia Medical LLC and Roche\/Genentech; advisory boards with TP Therapeutics, Guardant Health, AnHeart Therapeutics, ChromaCode, and Rigal Pharmaceuticals (all: honoraria to institution); clinical trial support (to institution) from Syntrix Pharmaceuticals, Novartis, Merck, AnHeart Therapeutics, AstraZeneca, Sorrento Therapeutics, Guardant Health, Philogen, Nuvation Bio, and Black Diamond Therapeutics.  KL reports consulting activities with Amgen, AstraZeneca Interdisciplinary Corporation, Boehringer Ingelheim Pharmaceuticals, Janssen Biotech, Novartis; advisory boards with AstraZeneca, Janssen, Jazz Pharmaceuticals, Mirati Therapeutics, Regeneron, Takeda, and Targeted Oncology (all: honoraria to institution); CME activities with OncLive, MJH Life Sciences, Mechanisms in Medicine, Medscape WebMD, MD Outlook and Targeted Oncology (all: honoraria to institution); Research support (to institution) from AstraZeneca and Mirati Therapeutics. KP reports consulting fees to institution from Jazz Pharmaceuticals, Guardant Health, Regeneron; Rigel Pharmaceuticals, AstraZeneca and Immunity Bio; honoraria to self for CME activities from MJH Life Sciences and Clinical Education Alliance; honoraria to institution for presentations from Dava Oncology and Intellisphere; publication fee support from Takeda; and travel support from Dava Oncology. ASM reports honoraria to institution from AbbVie, Abdera, AstraZeneca, BMS, Genentech, Genprex, Gilead, Immunocore, Johnson & Johnson Global Services, Orion Corporation, RayzewBio and Sanofi Genzyme; Honoraria to self from IDEOlogy Health; is a non-remunerated member of the Friends of Patan Hospital Board of Directors; and has received manuscript publication support from Genentech and Janssen, study funding and subsequent publication processing fees from Bristol Myers Squibb. MPG reports personal fees for CME activities from AXIS, BroadcastMed, DAVA Oncology, IDEOlogy Health, MJH Life Sciences, PeerView, Physicians\u2019 Education Resource, Research to Practice, Total Health Conferencing; consulting fees to Mayo Clinic from AstraZeneca, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd., BeiGene USA, Biotheranostics, Biotheryx, eChinaHealth, EcoR1, Eli Lilly and Company, Engage Health Media, Genentech, Incyclix, Lilly, Laekna, Novartis, Pfizer, RNA Diagnostics, Seattle Genetics, Sermonix Pharmaceuticals, Stemline Therapeutics, TerSera Therapeutics\/Amplity Health; grant funding to Mayo Clinic from AstraZeneca, ATOSSA Therapeutics, Biotheryx, Lilly, Loxo, Pfizer, Sermonix, SimBioSys; travel support from Lilly. All of the other authors have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1134"}}